Uncovering the Secret to Breast Cancer Breakthroughs with Dr. Dennis Slamon We weren’t able to create a summary for you. Refresh your page to try again. Slamon spoke with Denise Heady, science communications and media relations manager for the UCLA Health Jonsson Comprehensive Cancer Center, about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research. Slamon spoke with Denise Heady, science communications and media relations manager for the UCLA Health Jonsson Comprehensive Cancer Center, about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breastcancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breastcancer patients. Slamon spoke with Denise Heady, science communications and media relations manager for the UCLA Health Jonsson Comprehensive Cancer Center, about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research. Together, they explore the pioneering research and collaborations that eventually led to the FDA approval of Herceptin—a life-saving therapy for HER2-positive breastcancer. Nov 25, 2023 · When Dr. Abraham asked about the intersection of industry and academic medicine in the drug development process, Dr. Slamon responded: “For a long time, industry had its own big science groups that were doing their own internal research, and they still do. Aug 19, 2025 · In the early 2000s, a team of researchers led by Slamon led the discovery program that found that cyclin-dependent kinase inhibitors are effective in treating HR-positive breastcancer. Slamon, M.D., Ph.D., a UCLA oncologist and researcher, transformed breastcancer treatment through his pioneering identification of the HER2/neu oncogene, amplified in roughly a quarter to a third of breastcancers.
